Experimental drug zilganersen aims to slow rare brain disease
NCT ID NCT04849741
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether zilganersen (ION373) can improve or stabilize motor function in people with Alexander disease, a rare genetic brain disorder. Fifty-four participants aged 2 to 65 will receive either the drug or a placebo injected into the spine. The study measures walking speed and symptom severity over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zilganersen (ION373)
What this could lead to
If successful, this could lead to the first treatment that slows or stabilizes the worsening of motor function in Alexander disease, offering patients a way to maintain abilities longer.
What could go wrong
This is an early-stage Phase 3 trial with only 54 participants, so results may not apply to all patients. The drug is injected into the spine, which carries risks like infection or nerve damage, and it may not improve symptoms for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALEXANDER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amsterdam Universitair Medische Centra - Academisch Medisch Centrum
Amsterdam, North Holland, 1105 AZ, Netherlands
-
Children's Hospital of Atlanta
Atlanta, Georgia, 30329, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Great Ormond Street Hospital for Children NHS Foundation Trust
London, WC1N 3JH, United Kingdom
-
Lucile Packard Children's Hospital Stanford
Palo Alto, California, 94304, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
McGill University Health Centre
Montreal, Quebec, H3A 0G4, Canada
-
Murdoch Children's Research Institute
Parkville, Victoria, 3052, Australia
-
National Center of Neurology and Psychiatry
Tokyo, Kodaira-shi, 187-8551, Japan
-
Ospedale Pediatrico Bambino Gesù
Roma, 165, Italy
-
Ospedale dei Bambini Vittore Buzzi
Milan, 20154, Italy
-
Pediatric Neurology Institute, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center
Tel Aviv, 6423906, Israel
-
University College London Hospitals NHS Foundation Trust
London, WC1N 3BG, United Kingdom